Fiore J J, Kelsen D P, Gralla R J, Casper E S, Magill G, Cheng E, Ochoa M
Cancer Treat Rep. 1985 Jun;69(6):591-4.
Adenocarcinoma of unknown primary origin (ACUP) is a common oncologic problem for which there is no standard therapy. Forty-two patients with metastatic tumor were identified as having ACUP after extensive evaluation failed to reveal a primary site of disease. They were treated with an investigational chemotherapy regimen consisting of vindesine and doxorubicin. Of the 38 evaluable patients, six (16%) had major responses to chemotherapy. The median duration of response was 4 months. The median survival of the responding patients has not been reached, but is greater than 8 months. The median survival of the nonresponding patients was 6 months. Vindesine and doxorubicin were well tolerated. The major toxicity was leukopenia, with a median wbc count nadir of 2600/mm. We conclude that the combination of vindesine and doxorubicin has some activity in ACUP, but does not improve the response rate seen with other regimens.
原发灶不明的腺癌（ACUP）是一个常见的肿瘤学问题，对此尚无标准治疗方法。42例转移性肿瘤患者在经过广泛评估仍未能发现疾病原发部位后，被确诊为ACUP。他们接受了由长春地辛和阿霉素组成的试验性化疗方案治疗。在38例可评估患者中，6例（16%）对化疗有显著反应。反应的中位持续时间为4个月。有反应患者的中位生存期尚未达到，但超过8个月。无反应患者的中位生存期为6个月。长春地辛和阿霉素耐受性良好。主要毒性为白细胞减少，白细胞计数最低点的中位数为2600/mm。我们得出结论，长春地辛和阿霉素联合用药在ACUP中有一定活性，但并未提高与其他方案相比的反应率。
